Apoe4 (Apolipoprotein E4) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Apoe4 (Apolipoprotein E4) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Apolipoprotein E4 (APOE4) is the major genetic risk factor for late-onset Alzheimer's disease (AD), approximately increasing AD risk 3-4 fold in heterozygotes and 10-15 fold in homozygotes [1][2]. As the most significant genetic determinant of AD risk, APOE4 has become a critical focus for understanding AD pathogenesis and developing targeted therapeutic interventions.
APOE4 differs from APOE3 (the reference allele) at one amino acid position:
This single cysteine-to-arginine substitution at position 176 dramatically alters protein behavior:
| Feature | APOE2 | APOE3 | APOE4 |
|---|---|---|---|
| AD Risk | 50-60% reduced | Baseline | 3-15x increased |
| Age of Onset | ~77-80 yrs | ~75 yrs | ~65-70 yrs (E4/E4) |
| Aβ Clearance | Enhanced | Normal | Impaired |
| Aβ Aggregation | Reduced | Intermediate | Accelerated |
| Lipid Binding | Reduced | Intermediate | Highest |
| LDLR Binding | Very Low | Normal | ~50% |
| Neuroinflammation | Anti-inflammatory | Neutral | Pro-inflammatory |
| CAA Risk | Lower | Baseline | Higher |
APOE4 status affects treatment response:
Apoe4 (Apolipoprotein E4) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Apoe4 (Apolipoprotein E4) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Genin E, et al. (2011). APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry, 16(9), 903-907. https://doi.org/10.1038/mp.2011.52
Farrer LA, et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA, 278(16), 1349-1356. https://doi.org/10.1001/jama.1997.03550160069041
Lambert JC, et al. (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 45(12), 1452-1458. https://doi.org/10.1038/ng.2802
Hashimoto T, et al. (2012). Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain, 135(Pt 7), 2155-2168. https://doi.org/10.1093/brain/aws127
Sperling RA, et al. (2019). Amyloid-related imaging abnormalities in the IMAGEMantle study. Alzheimer's & Dementia, 15(7), 872-881. https://doi.org/10.1016/j.jalz.2019.03.006
Liu CC, et al. (2017). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology, 13(2), 106-118. https://doi.org/10.1038/nrneurol.2016.178
Huang Y, et al. (2017). Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to analgesia. Current Opinion in Lipidology, 28(2), 139-147. https://doi.org/10.1097/MOL.0000000000000399
Koffie RM, et al. (2012). Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain, 135(Pt 7), 2155-2168. https://doi.org/10.1093/brain/aws127